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An overall hypothesis for benzene-induced leukemia is proposed. Key components of the hypothesis
include a) activation of benzene in the liver to phenolic metabolites; b) transport of these metabo-
lites to the bone marrow and conversion to semiquinone radicals and quinones via peroxidase
enzymes; c) generation of active oxygen species via redox cycling; d) damage to tubulin, histone
proteins, topoisomerase 11, other DNA associated proteins, and DNA itself; and e) consequent
damage including DNA strand breakage, mitotic recombination, chromosome translocations, and
aneuploidy. If these effects take place in stem or early progenitor cells a leukemic clone with
selective advantage to grow may arise, as a result of protooncogene activation, gene fusion, and
suppressor gene inactivation. Epigenetic effects of benzene metabolites on the bone marrow
stroma, and perhaps the stem cell itself, may then foster development and survival of the
leukemic clone. Evidence for this hypothesis is mounting with the recent demonstration that
benzene induces gene-duplicating mutations in human bone marrow and chromosome-specific
aneuploidy and translocations in peripheral blood cells. If this hypothesis is correct, it also potentially
implicates phenolic and quinonoid compounds in the induction of "spontaneous" leukemia in
man. - Environ Health Perspect 104(Suppl 6):1219-1225 (1996)
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Introduction
Benzene is an established human leuke-
mogen, but the mechanism by which it
produces leukemia remains unclear. This
article presents a hypothesis of how ben-
zene produces leukemia. The hypothesis
has a number of themes which postulate
that benzene is an unusual carcinogen. For
example, I propose that a number of
metabolites work in concert to produce its
effects and that the genotoxic effects that
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these metabolites produce are not simple
point mutations, but rather recombination
and chromosomal aberrations. The article
compares benzene to more classical car-
cinogens and then outlines the hypothesis
in detail.
Benzene, Not a
"Classic" Carcinogen
Textbooks tend to narrow our thinking as
to the way in which chemicals produce
cancer. "Classic" carcinogens, such as
benzo[a]pyrene, aromatic amines, and
aflatoxin, are thought to be activated to a
single, ultimate carcinogenic metabolite.
Typically these metabolites are highly
electrophilic and bind strongly to DNA in
a covalent fashion. Covalent binding of
this type is readily measured as bound
radioactivity. Classic carcinogens and their
metabolites are also highly mutagenic in
the Ames Salmonella test producing point
mutations and small deletions.
Benzene presents the exact opposite
scenario. It does not form a single highly
electrophilic metabolite. Its epoxide, ben-
zene oxide, is highly unstable and rapidly
rearranges to the major metabolite phenol.
Alternatively, it is metabolized via epoxide
hydrolase and dihydrodiol dehydrogenase
to catechol. None of the prominent
metabolites of benzene are "hard" elec-
trophiles and thus little binding to DNA is
detected as bound radioactivity when radi-
olabeled benzene is administered to experi-
mental animals (1). Benzene and the
majority of its metabolites are also not
mutagenic in the Ames Salmonella test (2).
They do, however, produce chromosomal
damage both in vitroand in vivo (2-5).
How is Benzene
Carcinogenic?
If benzene is not a "classic" carcinogen
binding to DNA and causing point muta-
tions, how, then, is it carcinogenic? I pro-
pose that benzene is carcinogenic by its
phenolic metabolites acting in concert to
produce DNA strand breaks, topoiso-
merase II inhibition, and damage to the
mitotic spindle. This leads to mitotic
recombination, chromosome transloca-
tions, and aneuploidy (the loss and gain of
whole chromosomes). These genotoxic
events will, in turn, cause the activation of
key protooncogenes, loss ofheterozygosity,
and inactivation of tumor suppressor
genes. If this takes place in bone marrow
stem or early progenitor cells, a leukemic
clone with selective growth advantage
could arise. Epigenetic effects of benzene
on the bone marrow stroma and progenitor
cells could then assist in the establishment
of a leukemic clone. Both genetic and epi-
genetic effects are therefore probably neces-
sary. Figure 1 outlines this hypothesis in
more detail.
The Role of Metabolism
and the Nature ofthe
Toxic Metabolites
To be carcinogenic, benzene must first be
metabolized in the liver, mainly via cyto-
chrome P4502E1. The major product is
phenol, which is either conjugated-primar-
ily to phenyl sulfate in humans-or further
hydroxylated by P4502E1 to hydroquinone.
Other major metabolites include catechol
and trans-trans-muconic acid. The latter is
presumed to be formed from the ring
opening of benzene epoxide via benzene
oxepin, or perhaps benzene dihydrodiol.
The intermediate product trans-trans-
muconaldehyde has genotoxic properties
and could play a role in benzene toxicity
(6,7). The selective toxicity ofbenzene to
blood and bone marrow would be hard to
explain if trans-trans-muconaldehyde were
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Figure 1. A mechanistic hypothesis of benzene-
induced leukemia.
the sole toxic metabolite since it would
have to be formed in the liver, travel to the
bone marrow, and induce selective toxicity.
It is difficult to imagine significant quanti-
ties of trans-trans-muconaldehyde escaping
hepatic glutathione and reaching the bone
marrow. Indeed, studies have shown that
little or no trans-trans-muconaldehyde is
likely to leave the liver(8).
There is now strong evidence that
quinones and related free radicals are the
ultimate toxic metabolites of benzene.
Specifically, I believe that 1,4-benzo-
quinone and its semiquinone radical
derived from hydroquinone are the most
critical toxic intermediates. The conver-
sion of phenol to diphenoquinone and
radical intermediates could also play an
important role, as could oxidation prod-
ucts of 1,2,4-benzenetriol. The latter,
although formed in small quantities, has
potent effects, and its formation in higher
amounts in mice may partly explain that
species' susceptibility to benzene toxicity
(9). Active oxygen species are produced
through autoxidation of 1,2,4-benzenetriol
which can cause strand breaks, microtubule
damage, micronuclei, and aneuploidy in
human cells (10,11). The role, if any, of
1,2-benzoquinone derived from catechol
remains unclear.
1,4-Benzoquinone and trans-trans-
muconaldehyde are similar chemically,
since they are both aoB-unsaturated dike-
tones. They are therefore likely to hit simi-
lar molecular targets and to have similar
toxic effects. Indeed, the combination of
hydroquinone and trans-trans-muconalde-
hyde has been shown to behighlytoxic (12).
An argument against the hypothesis
that quinones are the ultimate toxic
metabolites ofbenzene has been that their
precursors phenol, hydroquinone, and cat-
echol do not produce bone marrow toxicity
or leukemia. A logical explanation of this
apparent contradiction may be at hand,
however, related to the locations ofactivat-
ing and conjugating enzymes in the liver
(13). The liver is structurally divided into
three acinar zones labeled I, II, and III.
The primary site ofconjugating enzymes is
in zone I whereas that ofP4502E1 is zone
III. Blood flows from the hepatic portal
vein and artery first into zone I, then into
zone II, and finally into zone III before
exiting via a branch of the hepatic vein.
Thus, phenols and quinones entering the
liver will be conjugated immediately in
zone I, while benzene would escape conju-
gation and go directly to zone III where it
would be converted to phenol and hydro-
quinone and would then leave the liver in
both the free and conjugated forms. Far
more free, unconjugated phenols would be
expected to leave the liver after benzene
administration than after exposure to
phenol. Indeed, new pharmacokinetic mod-
eling predicts that bone marrow concentra-
tions offree phenol and hydroquinone will
be much higher after benzene administra-
tion than following phenol exposure. This
is the opposite to what we had previously
predicted with a pharmacokinetic model
that considered the liver a single, homoge-
neous compartment (14).
The new, heterogeneous liver compart-
ment model is likely to be much more
accurate, but experimental confirmation
will be difficult. This is because any free
phenol and hydroquinone reaching the
bone marrow is likely to be rapidly oxi-
dized via peroxidase enzymes to protein-
binding species. Only when this secondary
oxidation pathway approaches saturation at
very high benzene levels are there likely to
be free phenolic metabolites in the bone
marrow. Indeed, recent workby Henderson
and colleagues supports this idea (15).
Predicted metabolite concentrations would
therefore have to be measured as bound
and free forms.
A Rolefor Multiple
Metabolites
Evidence that multiple metabolites are
important in benzene toxicity has increased
in recent years. Together with David
Eastmond and Richard Irons, I reported
that phenol and hydroquinone, when
administered together, produced bone
marrow toxicity in mice that was very simi-
lar to that produced by benzene, whereas
alone they did not (16). We postulated
that peroxidase enzymes in the bone mar-
row, mainly myeloperoxidase (MPO), were
responsible for the secondary activation of
benzene's phenolic metabolites to toxic
quinones and free radicals (17). Further,
we showed that phenol would enhance the
MPO-dependent oxidation of hydro-
quinone to 1,4-benzoquinone. We next
showed that phenol increased the covalent
binding ofhydroquinone in bone marrow
(18) and that catechol would also stimulate
the peroxidase-dependent activation of
hydroquinone (19). Catechol and hydro-
quinone also produced a synergistic geno-
toxic effect in human lymphocytes (20).
Barale and co-workers have performed
experiments in mice that support this idea
of an interaction being important, by
showing that various combinations ofben-
zene metabolites are genotoxic (21). Studies
by Bodell and co-workers (22) and our
group (23) also support a multimetabolite
mechanism ofgenotoxicity.
Of great interest is the recent finding
that the target organs for benzene carcino-
genicity in rodents are rich in both peroxi-
dase and sulfatase enzymes (24). The bone
marrow, Zymbal gland, and harderian
gland are all rich in peroxidases, which can
activate phenols to toxic quinones and free
radicals. Sulfatases, which remove conju-
gated sulfate forming free phenols, are also
present at high levels in these target organs.
The selective distribution of these two
types ofenzymes in the body may explain
the accumulation of free phenol, hydro-
quinone, and catechol in the bone marrow
and the target organ toxicity ofbenzene.
MolecularTargets of
Benzene's Toxic Metabolites
All ofthe phenolic metabolites ofbenzene
can be oxidized by MPO and other peroxi-
dase enzymes to their respective semi-
quinone radicals and quinones (25). These
species are highly toxic by directly binding
to cellular macromolecules and generating
oxygen radicals through redox cycling. We
examined the ability of benzene and its
metabolites to produce oxygen radicals and
oxidative DNA damage in human cells in
vitro and in mice in vivo. (23) We used the
human myeloid cell line HL-60, which
contains high levels of MPO, for these
studies. HL-60 cells were incubated with
different benzene metabolites for 30 min,
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the DNA isolated and the amount of
8-hydroxy-2'-deoxyguanosine (8-OHdG)
measured by high-performance liquid
chromatography (HPLC) with electro-
chemical detection. The formation of
8-OHdG is reflective ofhydroxyl radical
attack on DNA. We found that phenol,
hydroquinone, and 1,2,4-benzenetriol all
increased the level of 8-OHdG in HL-60
cells. Catechol did not significantly increase
the 8-OHdG level, which is consistent with
the limited ability ofits quinone oxidation
product to redox cycle. We followed up
these findings in HL-60 cells with in vivo
studies in B6C3F1 mice. We administered
benzene at various dose levels and for
different time periods. We found that ben-
zene (200 mg/kg) produced a highly
significant, 5-fold increase in 8-OHdG in
bone-marrow DNA 1 hr after administra-
tion. This level later decreased to back-
ground levels, probably because ofrepair. A
recent study ofItalian gas station attendants
supports these findings in mice and HL-60
cells by showing that benzene exposure
correlated with increased 8-OHdG levels
in the urine (26). The metabolites most
likely responsible for this effect are phenol,
hydroquinone, and 1,2,4-benzenetriol.
When injected as a single dose into mice,
only benzenetriol significantly increased the
level of 8-OHdG in bone marrow DNA
(23). However, various combinations of
phenol, catechol, and hydroquinone also
significantly increased the 8-OHdG level
with phenol plus hydroquinone being the
most effective (23). This suggests that mul-
tiple metabolites play a role in producing
benzene-induced oxidative DNAdamage in
the bone marrow and adds further weight
to the hypothesis that multiple metabolites
are involved in benzene toxicity.
The formation of 8-OHdG in DNA
has been shown to cause point mutations,
especially G-T and A-C base substitu-
tions, and may also cause strand breakage if
not repaired. Plappert and co-workers (27)
recently used the single-cell gel (COMET)
assay to demonstrate that benzene clearly
has the ability to induce strand breakage in
mice. Earlier studies that did not find
strand breaks by alkaline elution simply
looked at inappropriate times (28). DNA
strand breaks were also increased in a dose-
dependent manner in mouse lymphoma
cells incubated with benzene and an S9
activating system or with its phenolic
metabolites (29).
Strand breakage may also result from
damage to key proteins associated with the
DNA. For example, recent studies using
accelerator mass spectrometry have shown
that metabolites ofbenzene bind selectively
to the histone fraction ofmouse bone mar-
row cells (K Turtletaub, personal commu-
nication). Damage to histone proteins
could alter DNA folding and packaging
and assist in the production of strand
breaks. Another key protein target for the
quinone oxidation products ofbenzene's
phenolic metabolites may be topoisomerase
II. Chen and Eastmond (30) recently pre-
sented convincing evidence that 4,4'-diphe-
noquinone (a phenol oxidation product)
and 1,4-benzoquinone (a hydroquinone
oxidation product) are potent inhibitors of
topoisomerase II, but not topoisomerase I
(31). This action is similar to the epido-
phyllotoxins etoposide and teniposide,
which are used in cancer chemotherapy.
These agents have been shown to be highly
mutagenic (32) and have been associated
with the production of secondary acute
myelogenous leukemias (33).
Upon binding to topoisomerase II,
epidophyllotoxins and perhaps benzene's
quinonoid metabolites, convert the enzyme
to a DNA poison (34). The enzyme func-
tions inappropriately and instead ofuncoil-
ing the DNA and removing loops, it can
break the DNA strands. Strand breakage
resulting from this action has the potential
to produce aberrant mitotic recombination
through the joining ofinappropriate DNA
strands. Likely outcomes of aberrant
recombination include cell death or the
production of stable structural chromo-
some aberrations, including chromosome
translocations, which may alter the differ-
entiation and growth activity ofthe cell. It
was recently shown that chromosome band
11q23 translocations are DNA topoiso-
merase II cleavage sites (35). Transloca-
tions involving band 1 1q23 occur with
high frequency in several types ofhuman
leukemia, especially cases occurring in
infants and young children (35,36).
Induction of Mitotic
Recombination and
Chromosome Translocations
by Benzene and Its
Metabolites
Evidence that benzene and its metabolites
produce mitotic recombination is increas-
ing. In vitro studies with mouse lymphoma
L5178Y cells showed that benzene was
mutagenic at the TK± locus in the presence
ofrat liver S9, a metabolic activation system
(29). The metabolites hydroquinone, cate-
chol, 1,2,4-benzenetriol, 1,4-benzoquinone
and trans-trans-mucondialdehyde were all
mutagenic in this test system. The muta-
genicity occurred at doses that were also
shown to cause DNAstrand breaks.
Recently, in a collaborative project with
the National Cancer Institute and Chinese
and California Environmental Protection
Agency investigators, we used the gly-
cophorin A (GPA) gene mutation assay to
examine the type ofmutations produced by
benzene in human bone marrow (37). The
GPA assay is able to detect a wide spectrum
ofmutational mechanisms, including point
mutations, deletions, and chromosome-
wide events or autosomal chromosome
interactions, such as mitotic recombination.
The GPAassay measures somatic cell muta-
tion frequency in peripheral erythrocytes.
Because mature erythrocytes lack a nucleus,
mutations expressed in erythrocytes must
have occurred exclusively in precursor ery-
throid cells or stem cells in the bone mar-
row. Since bone marrow is the target of
benzene toxicity, the GPA assay is highly
appropriate for mutational studies. The
GPA locus codes for a surface protein that
exists in two allelic forms, Mand N, on
erythrocytes. The assay measures the fre-
quency of variant cells that have lost
expression ofthe Mform in blood ofhet-
erozygous (MN) individuals. The variant
cells are either the phenotype N0 or NN.
N0 cells are thought to arise from point
mutation, deletions, or gene inactivation,
whereas NNcells presumably arise from
mitotic recombination, chromosome loss
with reduplication, or gene conversion.
We measured GPA mutation frequency
in 24 workers heavily exposed to benzene
and 23 matched controls in Shanghai,
China. We found that benzene caused a
highly significant increase in NNvariant
frequency, but not in N0. These results
suggest that benzene produces gene-dupli-
cating mutations, but not gene-inactivating
ones, at the GPA locus in human bone
marrow. The most likely mechanism by
which benzene does this is via mitotic
recombination. Further studies are needed
to confirm this finding and to examine the
ability of benzene metabolites to induce
mitotic recombination in human cells.
As outlined earlier, the most likely con-
sequence ofaberrant recombination caused
by benzene metabolites is the production
of stable chromosome translocations.
These are a common feature ofleukemic
cells (38). The Philadelphia chromosome,
which results from a reciprocal transloca-
tion between chromosomes 9 and 22, is
centrally involved in chronic myelogenous
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leukemia (39). The most common translo-
cation found in acute myelogenous
leukemia is a reciprocal translocation
between chromosomes 8 and 21 (t8;21)
(40). This results in the fusion of the
AML-l and ETO genes and produces a
highly active transcription factor that pro-
motes excessive growth and differentiation
paralysis in myeloid progenitor cells
(40-42). The t(8;21) translocation and
translocations at 1 lq23 are commonly
found in myeloid leukemias resulting from
treatment with epidophyllotoxins (43).
Since benzene metabolites appear to act in
a similar fashion to epidophyllotoxins
inhibiting topoisomerase II, causing DNA
strand breaks and structural aberrations, we
hypothesized that benzene may also cause
the t(8;21) translocation.
We are currently testing this hypothesis
using chromosome painting to detect
translocations between chromosomes 8 and
21 in the peripheral blood cells ofworkers
exposed to high levels of benzene (44).
Preliminary results suggest that benzene
increases the rate oftranslocations between
8 and 21 in highly exposed workers (45).
The t(8;21) has also been observed in con-
ventional cytogenetic analyses ofleukemias
associated with benzene or other chemical
exposures (46,47). The production of
t(8;21) translocations is therefore likely to
be involved in at least one pathway of
benzene-inducedleukemogenesis.
The Role ofAneuploidy
Another common genetic abnormality
found in leukemias is aneuploidy, the loss
and gain ofwhole chromosomes. Numerical
changes in C-group chromosomes 6 to 12
and X have been detected in the blood and
bone marrow of patients with benzene-
induced myelogenous leukemia, myelodys-
plastic syndrome, and pancytopenia. One
ofthese patients showed a clonal expansion
ofcells with trisomy 9, and a nonclone was
found in another. We have reported that
the benzene metabolite, 1,2,4-benzenetriol
induces aneuploidy of chromosome 9 in
HL-60 cells (48). Eastmond and co-work-
ers reported similar findings following
exposure ofhuman lymphocytes to hydro-
quinone (49). Elsewhere in this issue (50),
we report that benzene induces aneuploidy
of chromosome 9 in the lymphocytes of
exposed workers in a dose-dependent man-
ner. Benzene and its metabolites are there-
fore able to produce chromosome-specific
aneuploidy, which most likely plays a role
in leukemogenesis. Also in this volume,
Irons and Stillman (51,52) argue that
clonal cytogenetic abnormalities involving
the loss of all or part of chromosomes 5
and 7 are commonly detected in patients
who develop myelogenous leukemia after
antineoplastic therapy and benzene/solvent
exposure. The q arms of chromosomes 5
and 7 are thought to contain key genes,
perhaps suppressor genes, involved in
myeloid leukemia, and loss ofthis genetic
material could be a critical event. We have
therefore developed a procedure that uses
fluorescence in situ hybridization to detect
the loss of 5, 5q31, 7 or 7q in metaphase
spreads. We plan to apply this technique
on spreads prepared from the population
ofbenzene-exposed workers we began to
study in 1992 (44). Preliminary results
suggest a selective effect of benzene on
chromosome 7 (45), which would be
intriguing if borne out by further analysis
because of the proposed role ofgenes on
7q in leukemogenesis.
There are numerous mechanisms by
which chemicals can induce aneuploidy in
cells. These include damage to micro-
tubules in the mitotic spindle, kinetochore
detachment, and centriole damage (52,53).
More than 15 years ago, Irons and co-
workers showed that 1,4-benzoquinone
would selectively target tubulin and disrupt
microtubules in vitro. Further, they showed
that 1,4-benzoquinone was one ofthe most
potent disrupters known and proposed
tubulin as a key target in benzene toxicity
(54,55). Recently, we demonstrated that
hydroquinone and 1,2,4-benzenetriol
would disrupt the microtubular structure
of intact human cells using fluorescent
immunocytochemistry with an antitubulin
antibody (48). A generic mechanism for
aneuploidy production by benzene may
therefore be microtubule disruption.
It is difficult to imagine, however, how
disruption of microtubules would lead to
selective aneuploidy. Indeed, it may not.
Benzene's quinonoid metabolites may pro-
duce random aneuploidogenic on specific
chromosomes, but some alterations may be
lethal or cause premature apoptosis. Only
cells with nonlethal chromosome abnormal-
ities would then survive to be detectable.
It seems almost certain, however, that
chromosome-specific aneuploidy plays a
key role in the development and progres-
sion ofleukemia, as it does for many other
cancers (52,55).
Role of Epigenetic Events
It is clear that benzene is a genotoxic
carcinogen. However, other epigenetic phe-
nomena may play a role in benzene-induced
hematotoxicity. For example, Kalf and
co-workers have reported that benzene tox-
icity to the bone marrow can be prevented
by IL-1 administration (57). They postu-
late that hydroquinone is oxidized to
benzoquinone, which then inhibits the
conversion ofpre-IL-1 to the active form,
IL-1 (57). Further, they propose that this
effect occurs within the stromal cells ofthe
bone marrow, preventing the normal mat-
uration of progenitor cells, and that this
plays an important role in benzene-induced
aplastic anemia. Irons and co-workers (58)
have also shown an interesting effect of
hydroquinone pretreatment on the granu-
locyte-macrophage lineage ofhematopoi-
etic progenitor cells. His group has shown
that hydroquinone pretreatment increases
the number ofcolonies formed by recom-
binant GM-CSF-induced CFU-GM. At
concentrations as low as 10-9 molar,
hydroquinone produces this stimulatory
effect. This would suggest that hydroqui-
none causes the recruitment ofhematopoi-
etic progenitor cells into the granulocyte-
macrophage pathway. In theory, this
recruitment could provide more targets for
the genotoxic effects ofhydroquinone and
other metabolites (59). It also has been
shown that this phenomenon is specific to
chemicals that cause myeloid leukemias.
Leukemia may therefore result from ben-
zene inducing both altered differentiation
and genotoxic damage leading to a selective
growthadvantage for immature cells.
Hypothesis Overview
I propose that benzene is an unusual
carcinogen that does not produce cancer
through simple gene mutations. It may
actually represent an example of a separate
class of carcinogens that act by a similar
mechanism. This class may include diethyl-
stilbestrol, estrogen, and arsenic. I propose
that benzene is metabolized in the liver to a
variety of metabolites, which travel to the
bone marrow and act in concert to produce
its toxicity. I believe the phenolic metabo-
lites are the proximate toxic metabolites
and that the selective toxicity ofbenzene is
caused by the fact that its target organs are
rich in peroxidase and sulfatase enzymes.
The phenolic metabolites phenol, hydro-
quinone, catechol and benzenetriol are all
metabolized by peroxidases, such as MPO,
to highly toxic semiquinone radicals and
quinones. These, I believe are the ultimate
toxic metabolites ofbenzene, which produce
the characteristic pattern ofbenzene toxic-
ity in humans (leukopenia, aplastic anemia,
leukemia) and multiorgan carcinogenicity
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in peroxidase/sulfatase-rich tissues of
rodents (e.g., the Zymbal and Harderian
glands). Active oxygen species generated
by the redox cycling of quinone metabo-
lites may also play an important role. Of
interest is the recent finding that glu-
tathione conjugates of hydroquinone also
redox-cycle and these may be involved in
benzene toxicity (59).
The key molecular targets of quinones
and oxygen radicals generated from benzene
are most likely tubulin, histone proteins,
topoisomerase II, and other DNA-associ-
ated proteins. Damage to these proteins
would potentially cause DNA strand break-
age, mitotic recombination, chromosome
translocations, and malsegregation ofchro-
mosomes at anaphase to produce aneu-
ploidy. Ifthese effects took place in stem or
early progenitor cells a leukemic clone with
selective advantage to grow may arise, as a
result of protooncogene activation, gene
fusion, and suppressor-gene inactivation.
Epigenetic effects of benzene metabolites
on the bone marrow stroma, and perhaps
the stem cell itself, may then foster devel-
opment and survival of this leukemic
clone. Irons and Stillman (51,58) provide
further insights into the details of these
epigenetic events and propose that recom-
binational/aneuploidy changes in chromo-
somes 5 and 7, which produce losses ofkey
genetic material, are important in benzene-
induced leukemia. Our work supports the
hypothesis that changes in chromosome 7
play a key role. It is also possible that the
t(8;21) translocation and trisomy are also
involved in the development of leukemia
from benzene.
We are currently examining the role of
changes in chromosome 5, especially in the
5q31 region. There may be a number of
genetic pathways to benzene-induced
leukemia, but evidence is mounting that
the metabolites ofbenzene produce genetic
changes that are known causative factors in
myeloid leukemia, i.e., t(8;21) and aneu-
ploidy ofchromosomes 7, 8, and 9. We are
therefore close to understanding the mech-
anisms ofbenzene-induced leukemia, and
perhaps will soon have biological markers
that are of use in monitoring its effects in
exposed humans and predicting future
disease outcome.
Implications and Speculations
on the Causes of Leukemia
As part ofthe above hypothesis, I propose
that the proximate carcinogenic metabo-
lites of benzene are its phenolic metabo-
lites, phenol, hydroquinone, catechol, and
1,2,4-benzenetriol. These compounds are
quite common dietary constituents and
many are used in pharmaceutical prepara-
tions. For example, hydroquinone and cat-
echol are present in coffee and cigarette
smoke at quite high levels; phenol is pre-
sent in many foodstuffs and is a common
ingredient in numerous skin lotions, lip
balms, and mild anesthetics; hydroquinone
is also present in photographic developer.
It is perhaps not surprising that significant
background levels ofadducts deriving from
these compounds are found on human
blood proteins and in rodent bone marrow
(61). These compounds may therefore play
an important role in the development of
"spontaneous" leukemia in the human
population. It is also possible that environ-
mental benzene exposure plays some role in
this regard, since its effects may be addi-
tional and linear on the background. This is
discussed in greaterdetail elsewhere (62).
One must also consider that there are
numerous compounds in our diet, herbs,
pharmaceutical preparations, etc., that are
similar to the phenolic metabolites ofben-
zene. Phenols and quinones are widespread
in nature (63). Numerous compounds
have been found to be inhibitors oftopoi-
somerase enzymes (32,34). These com-
pounds could be especially important in
producing infant and early childhood
leukemias, since these commonly show
cytogenetic abnormalities at band 11q23
and t(8:21). As pointed out by Greaves
(36), in utero exposure is the most likely
cause of these leukemias. Topoisomerase
inhibitors may also contribute significantly
to adult leukemia incidence.
In narrowing our search for the causes
ofhuman leukemia, which apart from ion-
izing radiation remain largely unknown,
perhaps we should concentrate on pheno-
lics and compounds that affect the function
oftubulin/microtubules and topoisomerase
II. In this manner we may be able to pre-
vent the more than 80,000 leukemia/
lymphoma deaths that occur in the United
States each year and the multitude of
others that occur elsewhere in theworld.
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